Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/56—Materials from animals other than mammals
  • A61K35/60—Fish, e.g. seahorses; Fish eggs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/06—Fungi, e.g. yeasts
  • A61K36/062—Ascomycota
  • A61K36/064—Saccharomycetales, e.g. baker's yeast
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
  • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the field of the invention is treatment of cancer using hyperthermia.
• Hyperthermia i.e. exposure to temperatures that exceed normal body temperature
• hyperthermia is used to cause cancer cells to become more susceptible to chemotherapeutic agents or to radiation, and serves as an adjunct to such therapies.
• hyperthermia can be used to kill or damage cancer cells outright, however in such applications the temperatures used risk damage to normal cells.
• Hyperthermia can be applied locally, regionally, or to the whole body. Local hyperthermia is frequently used to produce very high temperatures that are restricted to a tumor site, resulting in thermal ablation. This is typically restricted to localized tumors that are exposed at the body surface or are accessible to a thin needle or probe. The size of tumors that can be treated in this fashion is also limited (generally to around two inches or less).
• Regional hyperthermia provides heat to a particular body region, such as a limb, organ, or body cavity. This can be accomplished by isolation perfusion (i.e. heating blood using an external device and directed it into the circulatory system supplying the region) or through the application of RF or microwave energy. The temperatures used for regional hyperthermia are too low to result in killing of cancer cells alone, so this technique is generally used as an adjunct to chemotherapy and/or radiotherapy.
• Temperatures as high as 107° F are used. It is theorized that this simulates fever and provides short term activation of certain immune cells, however whole body hyperthermia is currently used as an adjunct to chemotherapy.
• nanoparticles are thought to provide both a sensitizing effect and a source of heat via the application of a high frequency magnetic field.
• the need to localize such particles at the tumor site limits the utility of this approach.
• the side effects of the introduction of such magnetic nanoparticles are not clear.
• U.S. Patent Application Publication No. US 12/833207 proposes the use of conductive "buttons" positioned at a location proximate to a tumor.
• the conductive buttons can be made from metals such as gold, silver, aluminum, copper, or alloys and implemented in a variety of shapes and sizes.
• Cheon et al. the need to localize the conductive buttons at the tumor site and the targeted application of heat through the conductive buttons limits the utility of this approach.
• thermodynamic therapy system using a radiation transmission system to focus radiation to heat a treatment area in order to activate thermosensitive drug-containing liposomes.
• this approach does not disclose the specific drugs or adjuvants delivered by the thermosensitive drug-containing liposomes.
• the inventive subject matter provides compositions and methods in which selenium, fish oil, and/or selenium in combination with fish oil enhances or potentiates the effects of hyperthermia in reducing the proliferation of tumor cells.
• the selenium is in the form of selenium yeast, an amino acid derived from selenium yeast, and/or a peptide derived from selenium yeast.
• the inventive subject matter contemplates administering a sensitizer selected from the group consisting of selenium, fish oil, and a combination of selenium and fish oil to a cancer cell. It is contemplated that the selenium, fish oil, or a combination of selenium and fish oil are administered in sufficiently high doses depending on the application to increase the sensitivity of the target cancer cells to hyperthermia. In preferred embodiments, both selenium and fish oil are administered to advantageously increase the sensitivity of cancer cells to thermotherapy more than either fish oil or selenium alone.
• One embodiment of the inventive concept is a method of treating cancer cells that includes administering fish oil formulated as listed in Table 1 and inducing hyperthermia in a patient, where the fish oil is provided in an amount that provides a synergistic effect in reducing cancer cell proliferation.
• the fish oil is provided to the patient prior to the initiation of thermotherapy.
• the fish oil can be administered concurrently with thermotherapy.
• Another embodiment of the inventive concept is a method of treating cancer cells that includes administering selenium in the form of selenium yeast formulated as listed in Table 1 and inducing hyperthermia in a patient, where the selenium is provided in an amount that provides a synergistic effect in reducing cancer cell proliferation.
• the selenium is provided to the patient prior to the initiation of thermotherapy.
• the selenium can be administered concurrently with thermotherapy.
• a preferred embodiment of the inventive concept is a method of treating cancer cells that includes administering both fish oil and selenium in the form of selenium yeast formulated as listed in Table 1 and inducing hyperthermia in a patient, where the fish oil and the selenium is provided in an amount that provides a synergistic effect in reducing cancer cell proliferation.
• the fish oil and the selenium is provided to the patient prior to the initiation of thermotherapy.
• the fish oil and selenium can be administered concurrently with thermotherapy.
• thermotherapy can be administered at any temperature that increases the temperature of bodily tissue above a normal body temperature that is effective to reduce cancer cell proliferation by allowing better perfusion of cancer cells by oxygen and medication.
• thermotherapy can be administered at any temperature or combination of temperatures (e.g., a variable temperature hyperthermia session) between 37°C and 44°C.
• FIG. 1 is a bar graph depicting the effects of fish oil on the sensitization of MDA-MB- 231 breast cancer cells to hyperthermic conditions.
• FIG. 2 is a bar graph depicting the effects of fish oil and selenium, independently and in combination, on the sensitization of HT-29 colon cancer cells to hyperthermia temperatures.
• FIG. 3 is a bar graph depicting the effect of fish oil and selenium, independently and in combination, on the sensitization of BFTC-905 bladder cancer cells to hyperthermia
• FIG. 4 is a line graph depicting the effect of selenium, fish oil, and selenium/fish oil combinations of the proliferation of A549 lung cancer cells.
• FIG. 5 depicts the modulation of pAMPKa and COX-2 concentration by selenium yeast and fish oil.
• Hyperthermia is commonly induced in cancer-affected tissues, such as tumors, in order to reduce, inhibit, or reverse the growth of cancer cells. Often, hyperthermia therapy accompanies radiotherapy and chemotherapy in order to maximize efficacy of anti-cancer treatments.
• hyperthermia therapies do not incorporate the use of adjuvants to enhance the efficacy of hyperthermia in reducing the proliferation of cancer cells.
• Methods and compositions to enhance the anti-cancer effects of hyperthermia therapy using fish oil and selenium, individually or in combination, are disclosed herein.
• selenium can be in the form of selenium yeast, an amino acid derived from selenium yeast, and/or a peptide derived from selenium yeast. Approximately, as used herein, is defined as +5% of a stated value.
• the fish oil can contain about 220 mg docosahexaenoic acid (DHA) and about 330 mg eicosapentaenoic acid (EPA), which are precursors of particular eicosanoids that can reduce inflammation in the body.
• DHA docosahexaenoic acid
• EPA eicosapentaenoic acid
• the fish oil contains between about 110 mg and about 330 mg of DHA and between about 160 mg and about 500 mg of EPA. It is contemplated that DHA and EPA combined preferably does not exceed a total of three grams administered over 24 hours. However, it is also contemplated that DHA and EPA can be present in any quantity effective to reduce the proliferation of cancer cells when used in conjunction with thermotherapy.
• the combination of DHA and EPA can include between about 8% and about 80% of fish oil content depending on various factors, such as the source of the omega- 3 fatty acids, the processing of the oil, and the amounts of other ingredients in the oil.
• Sources of the fish oil include "oily" fish.
• herring, Spanish mackerel, salmon, halibut, tuna, anchovies, and sardines can be concentrated sources of omega-3 fatty acids.
• any marine source can serve as a source of fish oil containing omega-3 fatty acids.
• fish oil can be sourced from fish with lower concentrations of omega-3 fatty acids in their tissues, including, for example, cod, flounder, and snapper.
• a fish oil equivalent that includes omega-3 fatty acids can be sourced from marine algae directly instead of from oily fish.
• fish oil equivalents including EPA and/or DHA and suitable for use in formulations of the inventive concept can be obtained from non- marine sources.
• non-marine sources of EPA and DHA can include flaxseeds, chia seeds, hemp seeds, walnuts, and soybeans.
• selenium is administered in concentrations between about 500 ng/ml and about 1500 ng/ml.
• Selenium salts can be toxic if administered directly.
• the inventive subject matter contemplates sourcing selenium from selenium yeast, which is produced by cultivating Saccharomyces cerevisiae or another suitable yeast in a selenium-rich media. By cultivating yeast in a selenium-rich medium, selenium can substitute for sulfur in certain amino acids (e.g. methionine, cysteine), thereby providing a nontoxic source of selenium.
• selenium from animal sources can be in the form of selenomethionine, selenocysteine, and/or methylselenocysteine as well as proteins and peptides incorporating such amino acids.
• selenium can also be sourced from plants.
• bioconcentrated selenium can be sourced from plants.
• soluble selenium e.g., selenate
• selenium can be sourced from ocean water.
• FIG. 1 is a bar graph depicting the effects of fish oil on the sensitization of MDA-MB-231 breast cancer (“BC") cells to hyperthermic conditions.
• BC breast cancer
• BC cells were subjected to control (37° C) or hyperthermia temperatures (39 °C, 41 ° C).
• 37° C control at 37 °C
• 39 °C, 41 ° C hyperthermia temperatures
• each set of BC cells was (1) exposed to fish oil in concentrations of 0 ⁇ (control at 37 °C), 12.5 ⁇ , 25 ⁇ , and 50 ⁇ , (2) held at 37 °C, 39 °C, or 41 °C for two hours, (3) held in a C0 2 incubator for 72 hours, and (4) checked for cell proliferation as a percentage of that of control BC cells (cells at control temperature and 0 ⁇ fish oil
• the fish oil administered to the non-control concentration BC cells cultures contained 220 mg docosahexaenoic acid (DHA) and 330 mg of eicosapentaenoic acid (EPA) per gram.
• DHA docosahexaenoic acid
• EPA eicosapentaenoic acid
• BC cells held for two hours at temperatures in excess of37 °C and administered no fish oil showed marked reductions in cell proliferations as a percentage of the control BC cell culture.
• a reduction of at least 25% in the proliferation of BC cells was observed compared to the control BC cell culture.
• a further reduction of approximately 50% in the proliferation of BC cells was observed compared to the control BC cell culture.
• BC cells held for two hours at all tested temperatures and administered 12.5 ⁇ concentrations of fish oil showed an overall reduction in the proliferation of BC cells with mixed results at varying temperatures.
• a reduction of approximately 30% was observed compared to the BC control.
• a reduction of approximately 60% was observed compared to the BC control, indicating a synergistic effect.
• 41 °C a reduction of
• concentrations of fish oil showed an overall reduction in the proliferation of BC cells with mixed results at varying temperatures.
• a reduction of approximately 60% was observed compared to the control BC cell culture.
• a reduction of approximately 65% was observed compared to the control BC cell culture.
• a reduction of approximately 65% in the proliferation of BC cells was observed compared to the control BC cell culture.
• BC cells held for two hours at all tested temperatures and administered 50 ⁇ concentrations of fish oil showed an overall reduction in the proliferation of BC cells with mixed results at varying temperatures.
• a reduction of more than 75% was observed compared to the control BC cell culture.
• a reduction of approximately 80% was observed compared to the control BC cell culture.
• a reduction of approximately 85% in the proliferation of BC cells was observed compared to the control BC cell culture.
• concentrations of fish oil have when combined with elevated temperature on the cell cycle of the cancer cells.
• Figure 2 is a bar graph depicting the effects of fish oil and selenium, individually and in combination, on the sensitization of HT-29 colon cancer cells ("HT cells”) to hyperthermia temperatures.
• HT cells HT-29 colon cancer cells
• the sensitizing effects of selenium, fish oil, and selenium and fish oil in combination are evident in HT-29 colon cancer cells exposed to hyperthermia temperatures.
• HT cells were subjected to 37 °C (control) and hyperthermia temperatures (39 °C and 41 ° C). At each temperature, each set of HT cells was either (1) treated with 0.5 ⁇ g/ml of selenium, a 25 ⁇ concentration of fish oil, or both the 0.5 ⁇ g/ml of selenium and the 25 ⁇ concentration of fish oil, (2) held at 37 °C, 39 °C, or 41 °C for two hours, (3) held in a C0 2 incubator for 72 hours, and (4) checked for cell proliferation as a percentage of a control HT cell culture. The selenium was administered in the form of selenium yeast.
• the source of selenium is not limited to selenium yeast and can be administered using any method known in the art.
• incubation at 39° C reduced proliferation by about 20% relative to control HT cells and incubation at 41° C reduced proliferation by about 45% relative to control HT cells.
• HT cells held for two hours at all tested temperatures and treated with either 0.5 ⁇ g/ml of selenium, a 25 ⁇ fish oil concentration, or both the 0.5 ⁇ g/ml of selenium and 25 ⁇ fish oil showed an overall reduction in the proliferation of HT cells compared to the control HT cell culture.
• Figure 3 is a bar graph depicting the effect of fish oil and selenium, individually and in combination, on the sensitization of BFTC-905 bladder cancer cells (BFTC cells) to
• hyperthermia temperatures The sensitizing effects of selenium, fish oil, and selenium and fish oil in combination are evident in BFTC cells exposed to hyperthermia temperatures.
• BFTC cells were subject to control (37 °C ) and hyperthermia temperatures (39 °C and 41 ° C). At each temperature, each set of BFTC cells was either (1) treated with 0.5 ⁇ g/ml of selenium, a 12.5 ⁇ concentration of fish oil, or both the 0.5 ⁇ g/ml of selenium and the 12.5 ⁇ concentration of fish oil, (2) held at 37 °C, 39 °C, or 41 °C for two hours, (3) held in a C0 2 incubator for 72 hours, and (4) checked for cell proliferation as a percentage of the BFTC control.
• the selenium was administered in the form of selenium yeast. Again, it is contemplated that the source of selenium is not limited to selenium yeast and can be administered using any method known in the art.
• BFTC cells held for two hours at all tested temperatures and exposed to either 0.5 ⁇ g/ml of selenium, a 12.5 ⁇ fish oil concentration, or both the 0.5 ⁇ g/ml of selenium and the 12.5 ⁇ concentration of fish oil showed an overall reduction in the proliferation of BFTC cells compared to the BFTC control.
• incubation at 39° C reduced proliferation by about 13% relative to control BFTC cells and incubation at 41° C reduced proliferation by about 28% relative to control BFTC cells.
• Figure 4 is a line graph depicting the effect of selenium, fish oil, and selenium/fish oil combinations of the proliferation of A549 lung cancer cells (A549 cells).
• A549 cells were exposed to either 0 ⁇ (PBS), 25 ⁇ , 50 ⁇ , or 100 ⁇ fish oils. At each concentration of fish oil, each set of A5 cells was (1) exposed to either 0 ⁇ g/ml of selenium, 0.5 ⁇ g/ml of selenium, 1 ⁇ g/ml of selenium, 2 ⁇ g/ml of selenium, or 4 ⁇ g/ml of selenium, (2) held at 37 °C, 39 °C, or 41 °C for two hours, (3) held in a C0 2 incubator for 72 hours, and (4) checked for cell proliferation as a percentage of PBS.
• the selenium was administered in the form of selenium yeast. Again, it is contemplated that the source of selenium is not limited to selenium yeast and can be administered using any method known in the art.
• Each set of A549 cells held for two hours at higher concentrations of fish oil than PBS resulted in an overall reduction in the proliferation of A549 cells compared to PBS.
• the treatment of cell cultures with increasing concentrations (i.e. from 0.5-4 ⁇ g/ml) of selenium shows the effects on cell proliferation relative to control (PBS only) A549 cells as selenium concentration is increased, in addition to the effects of the fish oil on the A549 cells.
• Synergistic effects are particularly notable at high fish oil concentrations, where the addition of even low concentrations of selenium results in a profound decrease in cell proliferation relative to that of fish oil or selenium (either individually or additively).
• Table 1 shows the effects of fish oil and selenium on cell cycle distribution of MDA-MB breast cancer cells (MDA-MB cells) at 39° C and 41° C.
• the concentration of fish oil represents its DHA content. Each gram of fish oil contains 220 mg DHA and 330 mg EPA. Cells were incubated at hyperthermia temperatures for 2 hours and then placed in a C02 incubator for 72 hours before a cell cycle analysis was performed. Selenium was administered in the form of selenium yeast. As shown, the use of selenium, fish oil, and selenium and fish oil in combination leads to a significant redistribution of cell cycle occupancy of these cells under hyperthermia condition. Specifically, the percentage of cells in subGl phase (which is associated with apoptosis) is increased.
• selenium, fish oil, and selenium and fish oil in combination can modulate the concentration of certain proteins in cancer cells.
• Figure 5 depicts the modulation of pAMPKa and COX-2 concentration by selenium yeast and fish oil. Increased AMPK signaling is thought to prevent proliferation and metastasis in tumor cells. COX-2 is thought to modulate cell proliferation and apoptosis in solid tumors, with COX-2 inhibition being investigated as a therapeutic mode.
• the Inventor found that selenium, fish oil, and selenium/fish oil combinations result in increased levels of AMPKa and reduced levels of COX-2 in A549 lung cancer cells (GAPDH is included as a control). Such effects may contribute to the enhancement and/or synergistic effects seen when these are used in combination with hyperthermia.
• Suitable formulations that incorporate fish oil and selenium yeast include the nutritional supplement formulation provided in Table 2, which incorporates fish oil and selenium yeast components along with other nutritional components.
• This nutritional supplement has been found to have a high level of acceptance and to have unanticipated beneficial anti-tumor activity in combination with conventional therapies.
• the Applicant believes that use of such a nutritional supplement can provide a beneficial enhancement of the hyperthermia therapy, and can do so at lower, relatively safe temperatures that are readily achievable using conventional approaches and safer for patient use. The provision of such a safety margin in regards to body and local temperature can lead to broader acceptance and use of this non-toxic therapeutic mode.
• Vitamin D3 25 5000 IU
• Vitamin A Acetate 500 100000 IU
• composition shown in Table 2 includes components that have various physiological and biochemical effects, including anti-inflammatory activity, lowering of blood glucose levels, lowering of cholesterol, and anti-tumor activity. Other components provide supplementation of necessary vitamins, minerals, and amino acids at elevated levels. Other components (e.g.
• composition shown in Table 2 also includes certain flavorants (e.g. brown sugar, honey, vanilla flavor and masking agent) that serve to improve palatability and acceptance.
• Certain components e.g. honey, brown sugar, milk, rice protein, casein
• honey, brown sugar, milk, rice protein, casein can provide both flavor and caloric energy.
• such flavorants can be excluded without negatively impacting the effectiveness of the nutritional supplement, thereby providing a functional nutritional supplement that includes only essential components.
• components of a nutritional supplement of the inventive concept can be provided as powders, granules, liquids, suspensions, and/or emulsions.
• components of the nutritional supplement are provided as powders and/or granules.
• components of the nutritional supplement are provided in relative amounts as indicated in Table 2.
• the components of the nutritional supplement are provided as a single, mixed formulation.
• components of the nutritional supplement can be provided as a kit or similar assembly containing different components of the formulation segregated or packaged separately (for example, to provide different storage conditions conducive to component stability).
• Components shown in Table 2 can be provided as a single formulation (for example, as a pill, tablet, capsule, powder, liquid, suspension, etc.) or can be segregated into different formulations (for example, as pills, tablets, capsules, powders, liquids, suspensions, or combinations thereof).
• the amounts shown in Table 2 are exemplary, and represent typical daily dosages provided to an adult of normal stature and otherwise normal health. These amounts can be adjusted to account for differences in body mass, gender, medical condition, etc. For example, a relatively small patient weighing 40 kilos or less may receive benefit from dosages provided at or below the low end of the ranges provided, whereas a relatively large patient weighing 100 kilograms or more may require dosages provided at the high end of the ranges noted (or more).
• such a daily dose can be distributed as multiple doses throughout the day.
• the composition of each of such distributed doses can be identical. In other embodiments the composition of such distributed doses can be different, provided the summation of such doses provides the required supplementation.
• oils found in the formulation are at least consumer grade, and preferably highly purified (>95% pure).
• mineral components e.g. potassium, calcium, sodium, magnesium iron, manganese
• any safe and absorbable salt e.g. a halide salt, phosphate salt, carbonate salt, sulfate salt
• oxide e.g. gluconate
• organic complex e.g. gluconate
• chromium, molybdenum, selenium are supplied in the form of a yeast component, which can include provision as a yeast-containing powder or suspension and/or as a complex with a peptide or amino acid as a result of metabolism of such metals by yeast.
• preparation of various non-yeast fungi e.g. Cordyceps, Ganoderma Lucidum, Shiitake, Maitake, Turkey Tail
• a nutritional supplement of the inventive concept can be provided in amounts ranging from about 1 mg/kg body weight to about 100 g/kg body as a unit dose. Such a unit dose can be provided on a schedule ranging from 4 times a day to one time per week.
• the nutritional supplement can be provided as one or more pills or capsules.
• the nutritional supplement can be provided as a powder, granular, and/or liquid formulation that is added to a food or a beverage prior to consumption.
• the nutritional supplement can be provided as a food item, such as a food or candy bar.
• the nutritional supplement can be provided as a solution, suspension, or beverage that is suitable for oral consumption and/or provision by tube feeding.
• packaging that excludes light, moisture, and/or oxygen can be used to extend the shelf life of the nutritional supplement.
• a nutritional supplement of the inventive concept can be packaged with a hygroscopic agent (such as silica gel), a non- reactive gas (such as N2 or a noble gas), and/or under vacuum in order to extend shelf life.
• a hygroscopic agent such as silica gel
• a non- reactive gas such as N2 or a noble gas
• under vacuum in order to extend shelf life.
• Such packaging can, for example, provide a nutritional supplement of the inventive concept in single unit doses and additionally provide directions for preparation and/or dosing frequency.
• the present invention contemplates using hyperthermia in conjunction with nutritional supplements with varying concentrations of fish oil and selenium.
• Hyperthermia regimes consist of heating body tissue to supra-normal body temperatures to sensitize cancer cells to treatment methods or to directly kill cancer cells.
• hyperthermia regimes can be administered administered for 45-60 minutes over 4- 12 sessions.
• Hyperthermia can be applied locally, regionally, or to the whole body and sourced from microwave energy, radiofrequency energy, ultrasound energy, or any other source of energy sufficient to heat tissue to supra-normal temperatures.
• heat can be directly applied to the cancerous tissue, including, for example, by inserting a heated probe inside a tumor.
• a nutritional supplement containing a 25 ⁇ concentration of fish oil is administered to a patient to be ingested orally. After waiting a sufficient amount of time to allow the fish oil to be absorbed into the blood stream (e.g. , over a period of two hours), heat is applied to the cancerous tissue to raise the temperature of the tissue to supra-normal levels for a 45 minute duration.
• a microwave heating element can be applied locally to the surface of the skin of the patient above a tumor.
• a probe can be inserted into a tumor and heated.
• a patient can be instructed to wear a whole body suit and the patient's body can be heated to 39°C.
• a nutritional supplement containing 1000 ng/ml of selenium in the form of selenium yeast can be administered to a patient to be ingested orally. After waiting a sufficient amount of time to allow the selenium to be absorbed into the blood stream (e.g. , over a period of two hours), heat is applied to the cancerous tissue to raise the temperature of the tissue to supra-normal levels for a 60 minute duration.
• a microwave heating element can be applied locally to the surface of the skin of the patient above a tumor.
• a probe can be inserted into a tumor and heated.
• a patient can be instructed to wear a whole body suit and the patient's body can be heated to 39°C.
• a nutritional supplement containing a 25 ⁇ concentration of fish oil and 1000 ng/ml of selenium in the form of selenium yeast can be administered to a patient to be ingested orally. After waiting a sufficient amount of time to allow the fish oil and the selenium to be absorbed into the blood stream (e.g. , over a period of two hours), heat is applied to the cancerous tissue to raise the temperature of the tissue to supra-normal levels for a 55 minute duration.
• a microwave heating element can be applied locally to the surface of the skin of the patient above a tumor.
• a probe can be inserted into a tumor and heated.
• a patient can be instructed to wear a whole body suit and the patient' s body can be heated to 39°C.
• the fish oil and selenium individually or in combination and in any respective concentrations can be administered using any method effective to expose the cancer cells to the fish oil and/or the selenium.
• fish oil and selenium can be directly injected into the cancerous tissue.
• fish oil and selenium can be applied topically to the skin or to the outer most tissue of an organ to be absorbed into cancerous tissue.
• heat can be applied to the cancerous tissue using any method known in the art.
• a heated element can be directly applied to the cancerous tissue or tissue surrounding the cancerous tissue to transfer heat through conduction.
• a heating element giving of electromagnetic energy waves can be used to transfer heat including, for example, an infrared heating element.
• inventive subject matter provides many example embodiments of the inventive subject matter. Although each embodiment represents a single combination of inventive elements, the inventive subject matter is considered to include all possible combinations of the disclosed elements. Thus if one embodiment comprises elements A, B, and C, and a second embodiment comprises elements B and D, then the inventive subject matter is also considered to include other remaining combinations of A, B, C, or D, even if not explicitly disclosed.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Marine Sciences & Fisheries (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Inorganic Chemistry (AREA)
• Mycology (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Biotechnology (AREA)
• Alternative & Traditional Medicine (AREA)
• Engineering & Computer Science (AREA)
• Botany (AREA)
• Medical Informatics (AREA)
• Microbiology (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Indole Compounds (AREA)
• Medicines Containing Plant Substances (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=64562472

Family Applications (1)

Country Status (9)

Cited By (1)

Families Citing this family (4)

Citations (11)

Family Cites Families (53)

• 2018
  • 2018-06-13 TW TW107120417A patent/TWI823853B/zh active
  • 2018-06-13 WO PCT/US2018/037268 patent/WO2018231938A1/en not_active Ceased
  • 2018-06-13 EP EP18817547.5A patent/EP3638270B1/en active Active
  • 2018-06-13 KR KR1020207000881A patent/KR102773006B1/ko active Active
  • 2018-06-13 JP JP2019569250A patent/JP7336994B2/ja active Active
  • 2018-06-13 US US16/007,524 patent/US10905724B2/en active Active
  • 2018-06-13 IL IL271327A patent/IL271327B2/en unknown
  • 2018-06-13 CN CN202510222932.9A patent/CN120695037A/zh active Pending
  • 2018-06-13 CN CN201880048905.2A patent/CN111479578A/zh active Pending
  • 2018-06-13 CA CA3066742A patent/CA3066742A1/en active Pending
• 2021
  • 2021-01-30 US US17/163,419 patent/US11433105B2/en active Active
• 2022
  • 2022-07-27 US US17/874,540 patent/US11896624B2/en active Active
• 2023
  • 2023-06-07 JP JP2023093883A patent/JP2023105154A/ja active Pending

Patent Citations (11)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events